Intellia Therapeutics, Inc.
NASDAQIntellia Therapeutics fell 14% Thursday while short interest ticked up to 34.4% of float. Cost to borrow rose 25% week-over-week. ARK and Vanguard added over 2 million shares each in Q1. Analysts hold a Buy consensus with 13 Buy ratings, though targets range from $15 to $48. NTLA closed at $13.63 on April 24, down 14.1% on the day. The stock fell…
Snapshot as of 11 May 2026
Intellia Therapeutics fell 14% Thursday while short interest ticked up to 34.4% of float. Cost to borrow rose 25% week-over-week. ARK and Vanguard added over 2 million shares each in Q1. Analysts hold a Buy consensus…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NTLA — free to start on ORTEX.
Sign up for free →Open NTLA on ORTEX